within Pharmacolibrary.Drugs.ATC.A;

model A16AX06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.97,
    Cl             = 0.00011500000000000002,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0838,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0026333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A16AX06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Miglustat is an oral iminosugar used as a substrate reduction therapy for the treatment of type 1 Gaucher disease in adults with mild to moderate disease for whom enzyme replacement therapy is not an option. It is also approved for Niemann-Pick disease type C. It inhibits glucosylceramide synthase and thereby reduces the accumulation of glycolipid substrates.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Lyseng-Williamson, KA (2014). Miglustat: a review of its use in Niemann-Pick disease type C. <i>Drugs</i> 74(1) 61–74. DOI:<a href=&quot;https://doi.org/10.1007/s40265-013-0164-6&quot;>10.1007/s40265-013-0164-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24338084/&quot;>https://pubmed.ncbi.nlm.nih.gov/24338084</a></p></li><li><p>van Giersbergen, PL, &amp; Dingemanse, J (2007). Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. <i>Journal of clinical pharmacology</i> 47(10) 1277–1282. DOI:<a href=&quot;https://doi.org/10.1177/0091270007305298&quot;>10.1177/0091270007305298</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17720777/&quot;>https://pubmed.ncbi.nlm.nih.gov/17720777</a></p></li><li><p>Maegawa, GH, et al., &amp; Clarke, JT (2009). Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis. <i>Molecular genetics and metabolism</i> 97(4) 284–291. DOI:<a href=&quot;https://doi.org/10.1016/j.ymgme.2009.04.013&quot;>10.1016/j.ymgme.2009.04.013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19447653/&quot;>https://pubmed.ncbi.nlm.nih.gov/19447653</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A16AX06;
